ETP-46321 - CAS 1252594-99-2
Catalog number:
1252594-99-2
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
PI3K
Description:
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after oral dosing. ETP-46321 PK/PD studies showed time dependent downregulation of AKT(Ser473) phosphorylation, which correlates with compound levels in tumor tissue and demonstrating to be efficacious in a GEMM mouse tumor model driven by a K-Ras(G12V) oncogenic mutation. Treatment with ETP-46321 resulted in significant tumor growth inhibition.
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
ETP-46321; ETP46321; ETP 46321
MSDS:
Inquire
Current Developer:
Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
1.Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
Martínez González S1, Hernández AI, Varela C, Rodríguez-Arístegui S, Lorenzo M, Rodríguez A, Rivero V, Martín JI, Saluste CG, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán M, Alfonso P, García-Serelde B, Oyarzabal J, Rabal O, Mule Bioorg Med Chem Lett. 2012 May 15;22(10):3460-6. doi: 10.1016/j.bmcl.2012.03.090. Epub 2012 Mar 29.
Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein, we describe the optimization of imidazo [1,2-a] pyrazines, which allow us to identify compound 14 (ETP-46321), with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after oral dosing. ETP-46321 PK/PD studies showed time dependent downregulation of AKT(Ser473) phosphorylation, which correlates with compound levels in tumor tissue and demonstrating to be efficacious in a GEMM mouse tumor model driven by a K-Ras(G12V) oncogenic mutation. Treatment with ETP-46321 resulted in significant tumor growth inhibition.
2.Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.
Granda TG1, Cebrián D, Martínez S, Anguita PV, López EC, Link W, Merino T, Pastor J, Serelde BG, Peregrina S, Palacios I, Albarran MI, Cebriá A, Lorenzo M, Alonso P, Fominaya J, López AR, Bischoff JR. Invest New Drugs. 2013 Feb;31(1):66-76. doi: 10.1007/s10637-012-9835-5. Epub 2012 May 24.
Inhibitors of PI3K signaling are of great therapeutic interest in oncology. The phosphoinositide-3-kinase signaling pathway is activated in a variety of solid and non-solid tumors. We have identified an imidazopyrazine derivative, ETP-46321, as a potent inhibitor of PI3Kα [Formula: see text]. The compound was 6 times less potent towards PI3Kδ and more than 200 and 60 times less potent at inhibiting PI3Kβ and PI3Kγ and did not significantly inhibit the related phosphoinositide-3-kinase-related protein kinase family kinases mTOR or DNA PK (IC(50)'s > 5 μM), or an additional 287 protein kinases that were screened. ETP-46321 inhibited PI3K signaling in treated tumor cell lines, induced cell cycle arrest and inhibited VEGF-dependent sprouting of HUVEC cells. The compound was anti-proliferative and synergized with both cytotoxic and targeted therapeutics. The compound induced a reduction in the phosphorylation of Akt in U87 MG xenografts after a single treatment.
3.ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Aragoneses-Fenoll L1, Montes-Casado M1, Ojeda G1, Acosta YY2, Herranz J2, Martínez S3, Blanco-Aparicio C3, Criado G4, Pastor J3, Dianzani U5, Portolés P6, Rojo JM7. Biochem Pharmacol. 2016 Apr 15;106:56-69. doi: 10.1016/j.bcp.2016.02.005. Epub 2016 Feb 13.
Class IA phosphoinositide 3-kinases (PI3Ks) are essential to function of normal and tumor cells, and to modulate immune responses. T lymphocytes express high levels of p110α and p110δ class IA PI3K. Whereas the functioning of PI3K p110δ in immune and autoimmune reactions is well established, the role of p110α is less well understood. Here, a novel dual p110α/δ inhibitor (ETP-46321) and highly specific p110α (A66) or p110δ (IC87114) inhibitors have been compared concerning T cell activation in vitro, as well as the effect on responses to protein antigen and collagen-induced arthritis in vivo. In vitro activation of naive CD4(+) T lymphocytes by anti-CD3 and anti-CD28 was inhibited more effectively by the p110δ inhibitor than by the p110α inhibitor as measured by cytokine secretion (IL-2, IL-10, and IFN-γ), T-bet expression and NFAT activation. In activated CD4(+) T cells re-stimulated through CD3 and ICOS, IC87114 inhibited Akt and Erk activation, and the secretion of IL-2, IL-4, IL-17A, and IFN-γ better than A66.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products


PI3Kα inhibitor 1
(CAS: 1235449-52-1)

PI3Kα inhibitor 1 is an inhibitor of PI3Kα as well as HDAC and probably have antineoplastic activity. IC50: <0.1 μM.

CAS 1431697-78-7 CAL-130 Hydrochloride

CAL-130 Hydrochloride
(CAS: 1431697-78-7)

In the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed ...

CAS 1383716-46-8 VPS34 inhibitor 1

VPS34 inhibitor 1
(CAS: 1383716-46-8)

VPS34 inhibitor 1 is a potent and selective inhibitor of VPS34 (IC50= 15 nM). Vps34 is a phosphoinositide 3-kinase (PI3K) class III isoform that has attracted m...

CAS 1032568-63-0 Copanlisib

Copanlisib
(CAS: 1032568-63-0)

Copanlisib, also known as BAY 80-6946, is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BAY 80-6946 inhibits the activat...

MLN1117
(CAS: 1268454-23-4)

MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.

Seletalisib
(CAS: 1362850-20-1)

Seletalisib is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by UCB.It is a Immunomodulator. Phaes I clinical trials for Plaque psoriasis...

GDC-0084
(CAS: 1382979-44-3)

GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...

CAS 1201438-56-3 Duvelisib

Duvelisib
(CAS: 1201438-56-3)

Duvelisib, also known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms o...

CAS 1202777-78-3 BKM120

BKM120
(CAS: 1202777-78-3)

BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...

CAS 1172118-03-4 PI3Ky inhibitor 1

PI3Ky inhibitor 1
(CAS: 1172118-03-4)

PI3Ky inhibitor 1 is a potent PI3Ky inhibitor.

CAS 1349796-36-6 XL-765, SAR245409,

XL-765, SAR245409,
(CAS: 1349796-36-6)

CAS 1218777-13-9 CAY10505

CAY10505
(CAS: 1218777-13-9)

CAY10505 is a phosphatidylinositol 3-kinase-γ inhibitor, was found to significantly improve acetylcholine-induced endothelium dependent relaxation, serum nitrat...

CAS 957209-68-6 NVP-QAV-572

NVP-QAV-572
(CAS: 957209-68-6)

NVP-QAV-572 is a potent PI3K kianse inhibitor.

AM-9635
(CAS: 1338483-10-5)

AM-9635 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-9635 exhibits good cellular potency (in vitro pAKT IC50 = 4.2 nM ). AM-9635 can...

Duvelisib R enantiomer
(CAS: 1261590-48-0)

The R isomer analogue of Duvelisib which is a high selective PI3K δ/γ inhibitor.

CAS 956958-53-5 XL147

XL147
(CAS: 956958-53-5)

Pilaralisib is a Class 1 phosphatidylinositol 3 kinase (PI3K) family inhibitor. It is an orally bioavailable small molecule, targeting the class I PI3K family o...

TGR-1202
(CAS: 1532533-67-7)

TGR-1202, also known as RP5264, is a highly specific, orally available, PI3Kdelta inhibitor which is approximately 1000 -fold selective over alpha isoform, >30-...

AM-0687
(CAS: 1259522-94-5)

This active molecular is a selective PI3Kδ inhibitor. PI3Kδ is hyperactivated in B-cell malignancies and plays a vital role in the B-cell receptor pathway. AM-0...

CAS 1174428-47-7 SF2523

SF2523
(CAS: 1174428-47-7)

SF2523 is a dual inhibitor of phosphatidylinositol 3-kinase and bromodomain-containing protein 4 with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for ...

CAS 1312445-63-8 NVP-BKM120 Hydrochloride

NVP-BKM120 Hydrochloride
(CAS: 1312445-63-8)

NVP-BKM120 Hcl(BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively.

Chemical Structure

CAS 1252594-99-2 ETP-46321

Quick Inquiry

Verification code

Featured Items